News

Nivolumab Does Not Improve OS vs GEM/PLD in Platinum-Resistant Ovarian Cancer

10/30/2020

Nivolumab did not improve survival versus gemcitabine and pegylated liposomal doxorubicin (GEM/PLD) in platinum-resistant ovarian cancer in the phase 3 NINJA trial.

Nivolumab did not improve...

10/30/2020

Oncology

News

Olaparib Maintenance Beneficial for Ovarian Cancer With BRCA Mutation

10/14/2020

Patients with BRCA-mutated ovarian cancer given maintenance olaparib after first-line platinum-based chemotherapy had extended rates of PFS and RFS, according to findings from the SOLO1 trial.

Patients with BRCA-mutated...

10/14/2020

Oncology

News

Rucaparib Extends PFS in Ovarian Cancer, Despite Toxic Effects

09/15/2020

Focusing on patient-centered outcomes from the ARIEL3 trial, rucaparib extended PFS in the maintenance setting for ovarian cancer despite toxicities.

Focusing on patient-centered...

09/15/2020

Oncology

News

Early Diagnosis of Ovarian Cancer Possible With Papanicolaou Tests

08/26/2020

Tumor-specific TP53 variants were detected in Papanicolaou tests for routine cervical cancer screenings up to 6 years before ovarian cancer diagnosis.

Tumor-specific TP53 variants...

08/26/2020

Oncology

News

Cancer Cells in Endometrial Cysts Could Lead to Earlier Ovarian Cancer Detection

08/17/2020

Researchers have found that EAOC often occurs within 36 months of follow-up for endometrial cysts, suggesting that cancer cells are in endometrial cysts.

Researchers have found that EAOC...

08/17/2020

Oncology

News

Guadecitabine Yields Modest Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer

07/23/2020

Guadecitabine as a primer for pembrolizumab has modest anti-tumor activity in patients with advanced, platinum-resistant, recurrent ovarian cancer.

Guadecitabine as a primer for...

07/23/2020

Oncology

News

Gemcitabine–Berzosertib Combo Beneficial for Recurrent, Platinum-Resistant Ovarian Cancer

07/16/2020

Berzosertib plus gemcitabine yielded a benefit over gemcitabine alone in patients with platinum-resistant, high-grade ovarian cancer, according to results from a phase 2 trial.

Berzosertib plus gemcitabine...

07/16/2020

Oncology

News

Quiz: Carboplatin Plus Pegylated Liposomal Doxorubicin and Bevacizumab for Recurrent Ovarian Cancer

06/24/2020

True or false: Carboplatin plus pegylated liposomal doxorubicin and bevacizumab has been posited as a new standard treatment option for patients with recurrent ovarian cancer.

True or false: Carboplatin plus...

06/24/2020

Oncology

News

Investigator-Assessed PFS Reliable Alternative to BICR in Ovarian Cancer Clinical Trials

06/24/2020

Researchers in the VELIA clinical trial suggest that investigator-assessed PFS in ovarian cancer trials is a reliable alternative to assessment via blinded independent central review (BICR).

Researchers in the VELIA...

06/24/2020

Oncology

News

Hydroxychloroquine Plus Itraconazole Shows No Antitumor Activity in Advanced EOC

06/22/2020

Although hydroxychloroquine plus itraconazole was feasible in heavily pre-treated patients with platinum-resistant EOC, the regimen did not demonstrate antitumor activity.

Although hydroxychloroquine plus...

06/22/2020

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology